Source: Eur Respir Rev, 26 (145) 170033; 10.1183/16000617.0033-2017



Rating:

Share or cite this content

Citations should be made in the following way:
Michele R. Schaeffer, Yannick Molgat-Seon, Christopher J. Ryerson, Jordan A. Guenette. Supplemental oxygen and dypsnoea in interstitial lung disease: absence of evidence is not evidence of absence. Eur Respir Rev, 26 (145) 170033; 10.1183/16000617.0033-2017

Member's Comments

No comment yet.

Related content which might interest you: Short-term effects of supplemental oxygen during exercise in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – Hot topics in pulmonary rehabilitation Year: 2019 Chronic obstructive pulmonary disease: current burden and future projections - Supplementary material Source: Eur Respir J 2006; 27: 397-412 Year: 2006 Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment Source: International Congress 2016 – IPF treatment I Year: 2016 Diffuse pulmonary ossification (DPO) in the absence of interstitial fibrosis: CT findings and clinical correlates Source: Annual Congress 2011 - Vascular and parenchymal imaging Year: 2011 Addition of respiratory hospitalizations 24weeks prior to the ILD-GAP model to predict mortality in chronic interstitial lung disease Source: International Congress 2016 – Clinical aspects of ILD Year: 2016 Impact of long-term oxygen therapy on systemic inflammation, morphological changes of red blood cells, pulmonary hemodynamics and diaphragm function in patients with chronic obstructive pulmonary disease. Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018 Beyond the lungs in fibrotic interstitial lung disease: does supplemental O2 improve skeletal muscle oxygenation and fatigue? Source: Virtual Congress 2020 – Exploring respiratory function Year: 2020 Low apoptosis rate as a reason of local immune cell accumulation in interstitial lung diseases (ILD). The role of cytokine network Source: Eur Respir J 2006; 28: Suppl. 50, 826s Year: 2006 No evidence for interstitial lung oedema by extensive pulmonary function testing at 4,559 m Source: Eur Respir J 2010; 35: 812-820 Year: 2010 Cleaning agents and chronic lung disease: does the evidence support a link with COPD? Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health? Year: 2018 A step test to assess exercise-related oxygen desaturation in interstitial lung disease Source: Eur Respir J 2007; 29: 330-336 Year: 2007 Activated lymphoid follicles, sign of an immune response, are present in early idiopathic pulmonary fibrosis (IPF) and increase with disease progression. Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012 Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF clinical Year: 2016 Effect of pulmonary rehabilitation on systemic inflammatory markers, muscle cross section area and functional parameters in interstitial lung disease Source: Annual Congress 2012 - New issues in pulmonary function Year: 2012 Etablishing rhesus model of pulmonary fibrosis (PF) for the new drug evaluation Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Scleroderma lung disease: A scleroderma physiologic index (SPI) derived from lung physiology and oxygen saturation Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 The role of secondary pulmonary hypertension (SPH) in the limited exercise tolerance of patients with interstitial lung disease (ILD) Source: Eur Respir J 2005; 26: Suppl. 49, 560s Year: 2005